InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: drkazmd65 post# 97937

Monday, 09/01/2014 1:03:18 PM

Monday, September 01, 2014 1:03:18 PM

Post# of 146195
If the Ebola effort results in a shortcut to "human trials", it would be a helluva proof of concept. Imagine the squirming and squealing from the shorts and bashers that would result from the successful use of Ebolacide in humans.

drkazmd65 said...

IMO - the fixation stems from a small set of facts:

1) Whether or not there is a deep revenue stream that would result from producing an Ebolacide isn't really that important - it is a very 'charismatic' (for lack of a better term) disease, with no real cure (yet) and that would gain a lot of media focus on a company that could come up with a cure. Good press for a company in NNVC's position (largely unknown) is a very positive thing even if revenue long-term isn't going to drive the company's future from treating Ebola.

2) Whichever treatment for a viral disease (Flucide, Ebolacide, Dengucide, HIVcide,....) gets into use first will provide a real-world proof of concept for NNVC's system of attacking and defeating viruses.

3) As there is no new news regarding Flucide one way or the other to talk about,..... the conversation has been drawn away to the more current speculation on what might be done to treat a disease that is more than a bit scary, and that is in news day in, day out.

If your point is to point out that Flucide is where this company will make or break it revenue-wise - I am in complete agreement with you. Ebolacide is a sidelight - if an interesting one - from the real 'game' that NNVC is playing.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News